BioAtla, Inc. Share Price
NASDAQ: BCAB | Micro CapBioAtla, Inc. Stock Performance
Open $3.40 | Prev. Close $3.37 | Circuit Range N/A |
Day Range $3.40 - $3.48 | Year Range $0.12 - $6.13 | Volume 850 |
Average Traded $3.45 |
BioAtla, Inc. Share Price Today
As of 11 August 2026, BioAtla, Inc.'s share price is $3.46. The stock opened at $3.40, compared to its previous close of $3.37. During today's trading session, BioAtla, Inc.'s share price traded between $3.40 and $3.48, with an average price of $3.44. Over the past 52 weeks, the stock has recorded a high of $6.13 and a low of $0.12. In terms of performance, BioAtla, Inc.'s share price has risen by 1300.81% over the last six months and is up 660.44% on a year-on-year basis.
BioAtla, Inc. Share Price Chart
BioAtla, Inc. Stock Fundamentals & Key Indicators
Market Cap $203.54M | PE Ratio (TTM) -3.43 | Dividend Yield N/A |
EPS (TTM) $-1.01 | Revenue (TTM) $2.00M | Return On Equity (TTM) 164.71% |
Profit Margin -2980.35% | Debt to Equity -0.61 | Quarterly Earnings Growth YoY 25.12% |
BioAtla, Inc. Quarterly Profit & Loss
All figures in USD
BioAtla, Inc. Annual Profit & Loss
All figures in USD
About BioAtla, Inc.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
BioAtla, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $3.35 | $3.45 | +4.55% |
Jul 2026 | $3.91 | $3.30 | -19.51% |
Jun 2026 | $3.93 | $4.10 | +3.80% |
May 2026 | $4.14 | $3.95 | -3.30% |
Apr 2026 | $0.12 | $4.08 | +2,406.13% |
Mar 2026 | $0.20 | $0.16 | -34.01% |
Feb 2026 | $0.25 | $0.25 | -7.84% |
Jan 2026 | $0.59 | $0.27 | -52.57% |
Dec 2025 | $0.95 | $0.56 | -37.43% |
Nov 2025 | $0.68 | $0.90 | +29.93% |
Oct 2025 | $0.74 | $0.69 | +1.61% |
Sep 2025 | $0.46 | $0.68 | +50.33% |
BCAB Share Price FAQs
What is BioAtla, Inc. share price today?
What is the 52 week high and 52 week low of BioAtla, Inc. stock?
What is BCAB's market capitalisation today?
What is BCAB's net income for the last quarter?
What is the 5 year returns of BCAB?
What is the high & low stock price of BCAB today?
Can I buy BCAB shares in India?